Literature DB >> 15879331

Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.

Courtney Reddrop1, Randal X Moldrich, Philip M Beart, Mark Farso, Gabriel T Liberatore, David W Howells, Karl-Uwe Petersen, Wolf-Dieter Schleuning, Robert L Medcalf.   

Abstract

BACKGROUND AND
PURPOSE: In contrast to tissue-type plasminogen activator (tPA), vampire bat (Desmodus rotundus) salivary plasminogen activator (desmoteplase [DSPA]) does not promote excitotoxic injury when injected directly into the brain. We have compared the excitotoxic effects of intravenously delivered tPA and DSPA and determined whether DSPA can antagonize the neurotoxic and calcium enhancing effects of tPA.
METHODS: The brain striatal region of wild-type c57 Black 6 mice was stereotaxically injected with N-methyl-d-Aspartate (NMDA); 24 hour later, mice received an intravenous injection of tPA or DSPA (10 mg/kg) and lesion size was assessed after 24 hours. Cell death and calcium mobilization studies were performed using cultures of primary murine cortical neurons.
RESULTS: NMDA-mediated injury was increased after intravenous administration of tPA, whereas no additional toxicity was seen after administration of DSPA. Unlike DSPA, tPA enhanced NMDA-induced cell death and the NMDA-mediated increase in intracellular calcium levels in vitro. Moreover, the enhancing effects of tPA were blocked by DSPA.
CONCLUSIONS: Intravenous administration of tPA promotes excitotoxic injury, raising the possibility that leakage of tPA from the vasculature into the parenchyma contributes to brain damage. The lack of such toxicity by DSPA further encourages its use as a thrombolytic agent in the treatment of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879331     DOI: 10.1161/01.STR.0000166050.84056.48

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

1.  Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.

Authors:  Andre L Samson; Simon T Nevin; David Croucher; Be'eri Niego; Philip B Daniel; Thomas W Weiss; Eliza Moreno; Denis Monard; Daniel A Lawrence; Robert L Medcalf
Journal:  J Neurochem       Date:  2008-09-15       Impact factor: 5.372

Review 2.  Intravenous thrombolytics for ischemic stroke.

Authors:  Andrew D Barreto
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

3.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

Review 4.  How to make better use of thrombolytic therapy in acute ischemic stroke.

Authors:  Geoffrey A Donnan; Stephen M Davis; Mark W Parsons; Henry Ma; Helen M Dewey; David W Howells
Journal:  Nat Rev Neurol       Date:  2011-06-14       Impact factor: 42.937

Review 5.  Imaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review.

Authors:  Albert J Yoo; Benjamin Pulli; R Gilberto Gonzalez
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-07

Review 6.  Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Authors:  Robert L Medcalf
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway.

Authors:  Fang Wu; Ramiro Echeverry; Jialing Wu; Jie An; Woldeab B Haile; Deborah S Cooper; Marcela Catano; Manuel Yepes
Journal:  Mol Cell Neurosci       Date:  2012-10-09       Impact factor: 4.314

Review 8.  tPA Modulation of the Blood-Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS.

Authors:  Linda Fredriksson; Daniel A Lawrence; Robert L Medcalf
Journal:  Semin Thromb Hemost       Date:  2016-09-27       Impact factor: 4.180

Review 9.  Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities.

Authors:  Venkata Prasuja Nakka; Anchal Gusain; Suresh L Mehta; Ram Raghubir
Journal:  Mol Neurobiol       Date:  2007-12-08       Impact factor: 5.590

10.  Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

Authors:  Nicola Logallo; Christopher E Kvistad; Aliona Nacu; Lars Thomassen
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.